Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Acti
Go back to Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Acti| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 200.65 +0.94 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $198.88 | 52 Week Low | $223.02 | |||
| Day High | $201.22 | P/E | 25.69 | |||
| Day Low | $198.42 | EPS | $7.81 | |||
| Volume | 335,293 | |||||
